E75.00
GM2 gangliosidosis, unspecified
Clinical Classification Guidelines
Medical Intelligence & Overview
GM2 gangliosidosis, unspecified, is a rare genetic disorder affecting the body's ability to break down fatty substances known as gangliosides. These substances accumulate in nerve cells, leading to progressive neurological damage. Because the exact form of the disorder isn't specified, this diagnosis covers various types of GM2 gangliosidosis, which include different inherited conditions that share similar symptoms and outcomes.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations affecting specific enzymes needed to break down gangliosides Autosomal recessive inheritance pattern, meaning both parents must carry the mutated gene Deficiency of the enzyme beta-hexosaminidase A or B, which is critical in the degradation of gangliosides in nerve cells
Key Symptoms: Progressive loss of motor skills and muscle weakness Cognitive decline and intellectual disability Seizures and abnormal movements Vision and hearing problems Cherry-red spot appearance in the retina Difficulty swallowing and feeding problems in infants Speech problems and regression of developmental milestones
Diagnostic & Treatment
Diagnosis Path: Blood tests to measure the activity of relevant enzymes like beta-hexosaminidase A and B Genetic testing to identify mutations in the HEXA or HEXB genes Neuroimaging studies, such as MRI scans, to observe brain atrophy and other structural changes Ophthalmologic examination to detect characteristic retinal changes
Treatment Protocols: Symptom management with medications for seizures and muscle spasticity Physical and occupational therapy to assist with mobility and daily activities Speech therapy for communication difficulties Nutritional support to address feeding challenges Psychosocial support for patients and families coping with the disease
Clinical Advice & FAQs
Billing Guidance
Is E75.00 a billable ICD-10 code?
Yes, E75.00 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E75.00?
Clinical documentation must specify the nature of GM2 gangliosidosis, unspecified and any associated comorbidities for accurate reporting.
Cite this Clinical Reference